We provide evidence that DYRK2 is involved in FBXW7 stability control in response to DNA damage, with important consequences on cell survival, and rendering cancer cells sensitive to the chemotherapy drug Paclitaxel and anti-cancer BET (Bromodomain and Extra-Terminal motif) inhibitors. This evidence concerns the gene DYRK2 and cancer.